Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 17/20 | 0.56 |
| ▸ | KDR | P35968 | 14/20 | 0.56 |
| ▸ | EGFR | P00533 | 5/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.53 |
| ▸ | YES1 | P07947 | 2/20 | 0.53 |
| ▸ | CSK | P41240 | 2/20 | 0.53 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.53 |
| ▸ | GAK | O14976 | 1/20 | 0.53 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.53 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.53 |
| ▸ | STK10 | O94804 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | FYN | P06241 | 1/20 | 0.53 |
| ▸ | LYN | P07948 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | HCK | P08631 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.53 |
| ▸ | FGR | P09769 | 1/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16747725 | 0.96 | SRC (0.61) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747771 | 0.95 | EGFR (0.61) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747711 | 0.95 | SRC (0.57) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747770 | 0.91 | EGFR (0.66) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747761 | 0.88 | EGFR (0.53) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747752 | 0.86 | SRC (0.58) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747746 | 0.86 | EGFR (0.51) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747762 | 0.86 | EGFR (0.60) | SRCKDREGFRLCKYES1 | |
| SCHEMBL16747731 | 0.85 | EGFR (0.60) | SRCKDREGFR | |
| SCHEMBL16742312 | 0.85 | SRC (0.53) | SRCKDREGFRLCKGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105916506-B | Quinazoline derivatives as inhibitors of TAM family kinases | 圣诺康生命科学公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3071204-B1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2019-02-20 | — | — | EP | disclosed |
| EP-3071204-B1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2019-02-20 | — | — | EP | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-9771333-B2 | Quinazoline derivatives as TAM family kinase inhibitors | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2017-09-26 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP (CA) | 2016-10-13 | — | — | US | disclosed |
| WO-2015077375-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | SIGNALCHEM LIFESCIENCES CORP. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297775-A1 | QUINAZOLINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS | MAP3K5, MAP3K1, MAP3K2 | SRC 329/4885KDR 597/4885EGFR 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.